Magseed Enabled Long-Term Localization of Axillary Lymph Nodes

Recruiting now · Not applicable

Conditions studied: Breast Cancer, Axillary Lymph Nodes

In brief

The purpose of this study is to provide prospective evidence that the use of Magseed/Sentimag in marking axillary lymph nodes and guiding surgical localization in patients with breast cancer following neo-adjuvant chemotherapy (NAC) is effective.

Key facts

Study ID

NCT03796559

Run by

Endomagnetics Ltd.

People needed

65

Starts

2019-06-13

Expected to finish

2026-05-01

Last updated by the study team

2024-09-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18 years or older at time of consent
• Histologically confirmed cT0-4, N1 breast cancer
• Axillary lymph node metastasis with pathologic confirmation by needle biopsy
• Clip placed in the sampled axillary lymph node before initiation of chemotherapy
• Planned for neo-adjuvant chemotherapy prior to surgical resection
• Eligible for targeted axillary dissection (defined as selective localization and removal of the clipped node and SLND) at the completion of neo-adjuvant chemotherapy
• ECOG performance status 0-2

You may not qualify if…

• Distant metastases
• Inflammatory breast cancer
• Prior ipsilateral axillary surgical procedure including SLND or axillary node excision
• Prior history of breast cancer in the ipsilateral breast
• History of lymphoma
• Subject is pregnant
• Previous radiation to the breast or axilla
• Pacemaker or other implantable cardiac device in the ipsilateral chest wall

Where it is running

• Baylor Medicine — Houston, Texas, United States (enrolling)
• MD Anderson Cancer Center — Houston, Texas, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.